44 results about "Intraocular Injections" patented technology

The present technology relates to an apparatus for intraocular injection comprising a plate adapted for being brought into contact with an eye and a guide operable to guide a needle into the interior of an eye, characterized in that it comprises means for displacing a superficial layer (1) of the eye over an underlying layer (2) of the eye as the plate is brought into contact with the eye before the needle is guided into the interior of the eye.

A method and article to treat ocular disease with Cyclosporin A alone or with compounds related to Cyclosporin A for intraocular injection or implantation. Treatment does not result in ocular toxicity and encompasses age related macular degeneration, retinitis pigmentosa, and retinopathy such as diabetic retinopathy.

The invention belongs to the field of pharmaceutical preparations, and relates to a long-acting sustained release preparation for preventing or treating retinal damage, and a preparation method thereof. The long-acting sustained release preparation takes erythropoietin (EPO) as an active component, takes dextran as a protective agent for the active component, and takes poly(lactic-co-glycolic acid), polylactic acid or polycaprolactone as a coating component to prepare sustained release microspheres, wherein the erythropoietin is coated by the poly(lactic-co-glycolic acid), polylactic acid or polycaprolactone. Proven by animal experiments, the sustained release microspheres of the long-acting sustained release preparation provided by the invention have the same protective actions on the ganglionic cells of damaged retinas by single vitreous chamber injection and repeated EPO protein vitreous chamber injection, and the sustained release microspheres are capable of avoiding a series of complications caused by many times of injection and overcoming the defects of repeated intraocular injection administration and gene therapy. The long-acting sustained release preparation provided by the invention adopts intraocular local administration, can reduce the dosage and treatment cost, and can not generate adverse effects on other organs or tissues in vivo.

The invention discloses an application of in-situ crosslinking hydrogel in preparing artificial vitreous bodies, which is characterized in that the in-situ crosslinking hydrogel is prepared by in-situ crosslinking after mixing a four-arm-end mercapto polyethylene glycol solution shown in the formula (I) and a polymer solution shown in the formula (II); wherein m in the formula (I) is an integer larger than 1, and n in the formula (II) is an integer larger than 1; and the two solutions are filled in eyes without vitreous bodies after mixing and can effectively form gel. A cell experiment and an animal in vivo experiment prove that the in-situ crosslinking hydrogel does not cause obvious inflammatory reaction and intraocular organ toxic reaction and can be used as the artificial vitreous bodies.

Described is an apparatus for intraocular injection comprising a body (50) adapted to accommodate a syringe (52) having a needle (54), an outer sleeve (57) telescopically coupled to the body (10), and at least two arms (61) hingedly coupled to the outer sleeve (57). Each of the arms (61) comprises a medial portion (65) adapted to encase at least a portion of the needle (54). When the body (50) moves distally relative 10 to said outer sleeve (57), the body (50) engages the arms (61) separating the medial portions (65).

The present invention relates to method for the treatment or prevention and of proliferative eye diseases including but not limited to: age related macular degeneration associated proliferative retinopathy, proliferative diabetic retinopathy, proliferative vitreoretinopathy, posterior capsular opacification, scaring and fibrosis after glaucoma filtration surgery, uveal melanoma, and retinoblastoma. The method comprises contacting cells in the eye by means of intra-ocular injection or infusion, with a drug that irreversibly inhibits cellular proliferation without causing extensive tissue necrosis or cytotoxicity. In a preferred embodiment the drug is bizelesin.

This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.

The invention belongs to the field of pharmaceutical preparations, and relates to a series multivalent cell-penetrating peptide delivery vector and a complex thereof, wherein the vector is built by the aid of multi-arm polyethylene glycol and cell-penetrating peptides or cell-penetrating peptide derivatives. The multivalent cell-penetrating peptide delivery vector has an octopus-like flexible structure, can be self-assembled with biological macromolecules, particularly genes to form the non-covalent complex and has strong biological macromolecule carrying, biological macromolecule delivery andocular tissue penetrating capacity, ocular tissue toxicity is avoided, biological macromolecule drugs can be effectively delivered to an intraocular portion or ocular fundus in a noninvasive way, andbiological macromolecule drug uptake by ocular tissues is increased. The complex formed by self-assembling the multivalent cell-penetrating peptide delivery vector with the biological macromoleculescan be used for eye drop administration, intraocular injection administration with poor compliance to patients can be replaced, and intraocular and ocular fundus disease treatment convenience and safety are enhanced.

The invention discloses application of pyrryl-substituted indole compound in curing glaucoma. The pyrryl-substituted indole compound can cure glaucoma through small-dose multiple intraocular injection medicine administration and eye drop multiple medicine administration. Furthermore, after the pyrryl-substituted indole compound is coated by lipidosome or is prepared into high-polymer-coated nanometer medicine, micro-ball drug medicine and hydrogel medicine, glaucoma can be cured continuously after intraocular medicine injection to achieve obvious medicine effects.

The present invention relates to a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial growth factor (anti-VEGF) preparation are fused. More particularly, the present invention relates to: a pharmaceutical composition for preventing and treating eye diseases, comprising, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused; a method for prepraring an anti-VEGF preparation, which overcomes resistance and has an improved efficacy, the method comprising the steps of transforming a host cell with a recombinant vector comprising a nucleic acid sequence encoding a fusion protein in which a tissue-penetrating peptide and an anti-VEGF preparation are fused, culturing the cell, and recovering a fusion protein from the cell; a method for treating eye diseases, comprising administering an effective dose of the fusion protein according to the present invention to a subject in need thereof; and use of the fusion protein according to the present invention for preparing an agent for treating eye diseases. Compared to conventional anti-VEGF preparations, the composition according to the present invention is considered to have an improved efficacy and be able to be used for treating patients having drug resistance, by inhibiting various growth factors related to new blood vessels, besides VEGF, and by decreasing pericyte coverage. In addition, since drug delivery ability into the choroid tissue is improved when performing an intraocular injection, the composition can be developed as eye drops by reducing an administered dosage or extending an administration cycle, and by improving ocular penetrability.

The invention provides application of pirfenidone in preparing anti-angiogenesis medicines, and provides a medicine for treating wet macular degeneration. Pirfenidone can be used for effectively inhibiting choroid angiogenesis, has an excellent activity by eye dropping and intraocular injection, can be used for treatment of angiogenesis diseases in ophthalmological department, in particular remarkable treatment effect to wet macular degeneration, and provides a novel choice for clinical administration.

An intraocular injection system for injecting a substance into an eye globe of an animal or human eye, the system comprising an injection device with a piercing member for injection of the substance into the eye globe, the intraocular injection system providing an automated piercing of the eye globe by the piercing member. The system further comprises a robotic manipulator carrying the injection device, the robotic manipulator adapted and configured to move the injection device to a pre-injection position, a detection device adapted and configured to detect a position of a patch placed onto the eye globe and to control the robotic manipulator to move the injection device to the pre-injection position, the pre-injection position being based upon the detected position of the patch on the eye globe.

The invention provides an anti-virus sustained-release drug capable of being subjected to intraocular injection, a preparation method and applications thereof, wherein the anti-virus sustained-releasedrug is a foscarnet insoluble salt micro-crystal, and the foscarnet insoluble salt is the polyvalent metal salt of foscarnet. The preparation method comprises: carrying out a reaction on the monovalent metal salt of foscarnet and the soluble salt of a polyvalent metal in water to obtain the system containing the foscarnet insoluble salt micro-crystal. According to the present invention, based onthe special requirement of the controlled-release and slow-release intraocular injection, the foscarnet insoluble salt micro-crystal slow-release system is designed, wherein the nominal drug loading can be more than 100%; the foscarnet insoluble salt micro-crystal slow-release drug can be lastingly, stably and slowly released in the vitreous cavity of rabbit eyes, the concentration of the foscarnet in the vitreous cavity is always maintained above the effective therapeutic concentration of sodium foscarnet, the sustained release period is up to 12 weeks, and the drug does not have obvious toxic effects and inflammatory reaction; and the foscarnet insoluble salt can be used as the anti-virus sustained-release drug capable of being injected into the vitreous cavity.

Described is an aid device for an intraocular injection comprising a skirt (1) having an aperture to receive an eye, and a cover (2) coupled to the skirt (1). The cover (2) has one or more guide holes (4) adapted to receive a needle.

Described is a medicament delivery device (1) comprising a needle (7) and a layer (9) of a composition coupled to at least a portion of the needle (7). The composition has a low viscosity and a low surface tension.

The present disclosure belongs to the field of pharmaceutical preparations and relates to the design of a series of lipophilic derivatives by using wild-type penetrating peptide penetratin. These penetratin derivatives have a strong ability to penetrate the ocular tissues and do not cause ocular tissue toxicity. As ocular absorption enhancers, non-invasive routes could be used to achieve intraocular drug delivery and increase the ocular bioavailability of drugs. These penetratin derivatives and the ophthalmic drug delivery system constructed by them are used for eye drop administration, which could replace the intraocular injection with poor patients compliance, which greatly enhances the convenience and safety of the treatment of intraocular and fundus diseases.

The invention belongs to the technical field of medical instruments, and in particular relates to a disposable intraocular injection syringe. The disposable intraocular injection syringe comprises a casing, a syringe needle and a plunger, and a plurality of distance markers can be evenly disposed on the syringe needle for determining the length of the syringe needle insertion. The color of the distance marker is red or orange. The injection syringe solves the problem that the existing intraocular injection does not have any reference for the doctor to refer to, and the doctor is difficult to judge the insertion depth of the syringe needle, which is unfavorable for a surgery. By increasing the depth of the syringe needle insertion by adding a plurality of the distance markers, the depth ofthe syringe needle insertion can be effectively determined, the safety of the intraocular injection is enhanced, and the distance marker is the eye-catching color such as red or orange to help the doctor notice the distance marker more easily.

The present invention provides a sustained drug delivery system for the treatment of age-related macular degeneration (AMD), comprising corticosteroid encapsulated nanoparticles incorporated into a thermoreversible hydrogel. The corticosteroid may be triamcinolone acetate (TA), dexamethasone, or loteprednol etabonate (LE). The proposed drug delivery system is nontoxic to ARPE-19 (retinal pigment epithelium) cells and significantly reduces VEGF (vascular endothelial growth factor) expression as compared to solutions of the coticosteroids. The present invention provides sustained delivery of the corticosteroid to the posterior segment of the eye, reducing the frequency of intraocular injections necessary to maintain therapeutic concentrations.